PMS39 Cost-Effectiveness Analysis of Certolizumab Pegol in Patients With Rheumathoid Arthritis from a Brazilian Private Perspective
Nov 1, 2012, 00:00
10.1016/j.jval.2012.08.1394
https://www.valueinhealthjournal.com/article/S1098-3015(12)03107-5/fulltext
Title :
PMS39 Cost-Effectiveness Analysis of Certolizumab Pegol in Patients With Rheumathoid Arthritis from a Brazilian Private Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)03107-5&doi=10.1016/j.jval.2012.08.1394
First page :
A446
Section Title :
Muscular-Skeletal Disorders
Open access? :
No
Section Order :
891